Inflammatory bowel disease (IBD) is a broad term that describes inflammation of the colon and small intestine. Crohn’s disease and ulcerative colitis are the most common types of IBD. It’s estimated that 5 million people worldwide live with a certain form of IBD.
A recent study shows that a protein, known as EZH2, may be a therapeutic target for IBD, and that another molecule, called protein kinase C (PKC) λ/ι, may help identify the severity of IBD. The researchers noted that PKC λ/ι seemed to be a tumor suppressor in the intestine. More details, refer to http://about.cusabio.com/c-19807.html